Introduction
Results
On the day of malaria diagnosis, Immunoglobulin (IgG) antibodies against GLURP, MSP3 and HRP II peptides were present in the blood of 75%, 41% and 60% of patients, respectively. 42 days later, the majority of patients had boosted their serum IgG antibody more than 1.2 fold. The increase in level of IgG antibody against the peptides was not affected by parasite density at diagnosis. The median CD4 + cell counts of PLWHAs and HIV negative individuals were not statistically different, and median post-infection increases in anti-peptide IgG were similar in both groups of patients.
Conclusion
In the majority (70%) of individuals, an infection of P. falciparum elicits at least 20% increase in level of anti-parasite IgG. This boost in anti-P. falciparum IgG is not affected by parasite density on the day of malaria diagnosis, or by HIV status.
Introduction
Plasmodium falciparum malaria is a leading cause of morbidity and mortality among children in sub-Saharan Africa [1] . Humoral immune responses are believed to be critical to effective immunity against Plasmodium falciparum [2] and play a key role in the development of naturally acquired immunity to malaria [3, 4] . However, protective immunity to malaria takes years to develop and requires repeated infections [5] . Earlier studies showed that transfer of serum or antibody preparations from partially immune residents of endemic regions to non-immune individuals has beneficial anti-malarial activity [6, 7] and that malaria specific antibodies are associated with protection against malaria [8, 9] . In general, high antibody levels are associated with reduced susceptibility to clinical malaria [10, 11] . However, how the malarial antibodies are acquired, maintained, and boosted by regular parasite infections in endemic areas is little understood. Yet, if natural boosting of anti-malaria immunity is well elucidated, the information can be of great value in developing robust vaccines against malaria. Earlier studies have shown that, when individuals are exposed to a new malaria infection, parasite-specific antibody levels usually increase markedly within 1 or 2 weeks after the onset of symptoms [12, 13] . The boosted antibodies normally decline fast after an infection is resolved, suggesting that protective memory for specific antibody response is not efficiently formed or is functionally impaired [14] . However, moderate antibody levels persist in many individuals. Such persistence has been shown to increase with age among young children [15] . Nevertheless, little is known about how ordinary P. falciparum infections work to build antibody responses to candidate vaccine molecules. We know very little about the extent to which natural infections will boost antibodies generated by candidate malaria vaccines. Candidate blood-stage vaccines include GMZ2 which has been tested in children and adults [16, 17] and comprises glutamine rich protein (GLURP) and merozoite surface protein 3 (MSP3) [9, 14, 18] . MSP3 and GLURP are believed to be involved in erythrocyte invasion [19, 20] and are important vaccine candidates [21, 22] . Indeed, high levels of specific cytophilic antibodies against MSP3 and GLURP have been reported to be associated with protection against clinical malaria [23, 24] . A few clinical trials where whole sporozoite or trophozoite forms were used as vaccine showed that development of host protective immunity against malaria can be achieved although such vaccination would require large numbers of parasites [25, 26] .
To gain further insight into the boosting of parasite specific antibody response following acute P. falciparum uncomplicated malaria, we investigated the antibody anamnestic response against three synthetic peptides [22] representing MSP3, GLURP, and Histidine Rich Peptide-II (HRPII) as well as parasitized erythrocyte (PE) lysate antigens. For this, we identified bloodsmear positive P. falciparum infected patients on day 0 (baseline), and collected venous blood for determination of parasite density, CD4
+ cell counts and sero-prevalence of antibodies aganist the synthetic peptides and to antigens in PE lysate. The patients were treated with artemether-lumefantrine (co-artem) according to standard treatment guidelines. At day 42, blood was collected from the convalescent patients to determine post-infection levels of specific Immunoglobulin (IgG) and sero-prevalence to the three peptides. The relationship between the levels of anti-peptide antibodies for day 0 and day 42 was assumed to represent a reasonable measure of secondary anti-P. falciparum antibody boost or increase after an acute episode of uncomplicated malaria.
Materials and Methods

Study area and subject enrolment
The study was conducted at Kasangati Health Centre (KHC) which is about 20 km, north east of Kampala the capital city of Uganda. Patients were recruited from the peri-urban villages located within 10 km of KHC. Kasangati lies within a moderate transmission area, with a peak transmission after the two main rainy seasons (February-March and September-October) every year. This study was conducted from November 2010 to January 2011 after the September-October rains. Consecutive sampling was used to enrol a prospective cohort of participants. Eligibility criteria included: uncomplicated malaria as defined previously [27] . In brief, inclusion criteria were history of fever in the previous 24 hr, axillary temperature 37.5°C, haemoglobin > 5 g/dl, P. falciparum mono-infection at any parasitemia, and informed written consent from participants or their parents or guardians for minors, agreement to come to the study clinic for 42 day follow up, age: more than 6 months. A detailed clinical examination was performed and data entered into a pre-tested study questionnaire. The first dose of Artemether-Lumefantrine was administered under direct observation to ensure compliance. If a patient vomited within 30 min, the dose was repeated. The remaining doses were administered at home unsupervised.
Human subject protection and ethics approval statement. A written informed consent was sought from all study participants before they were enrolled into the study. 
Clinical investigations and follow-up
On the day of recruitment, a finger prick blood specimen was taken and thick smears prepared and treated with Giemsa stain. Participants found to be smear positive for P. falciparum monoinfection were subsequently enrolled and a venous blood sample taken for sera and estimation of CD4 + cells. Follow-up of patients was arranged for day 42 and participants were asked to return to the clinic whenever they felt unwell within the subsequent 6 weeks. Follow-up consisted of history taking, a physical examination and blood smear examination. During the day 42 visit, a blood specimen was collected to re-assess the antibody levels. Standardized treatment was provided according to the national treatment guidelines. Patients who failed to return on day 42 were visited at their homes by our social worker and brought to the health unit for examination and medical care. Day 42 was selected as suitable for assessing the secondary antibody response after P. falciparum infection [28] and determining clinical outcome according to the WHO treatment guidelines [29, 30] .
CD4
+ T cell counts and examination of stained blood smears for parasites Thick smears were stained with 10% Giemsa stain for 10 min, sexual and asexual parasites were counted against every 200 white blood cells (WBCs). Results were multiplied by 40 to determine the parasite density (parasites/μL), assuming a normal WBC count of 8000 per μl [31, 32] . A smear result was judged to be negative if no parasites were seen after review of 100 highpower (400-fold magnification) fields. Final microscopy results were based on a rigorous quality control system, with re-reading of all blood smears by a second microscopist and resolution of any discrepancies by a third microscopist. The CD4 + T-cell counts were measured by a FACS Counter (Becton Dickinson, San Jose, CA, USA).
Measurement of serum IgG antibodies
P. falciparum serum antibodies to peptides MSP3, HRP II and GLURP were measured by enzyme linked immunorsobent assay (ELISA) essentially as described before [23] using respective synthetic peptides as antigen and peroxidase-conjugated anti-human IgG or anti-human IgM as secondary antibody. Briefly, microtiter plate wells were coated with 0.5 to 1 microgram of peptide per well, incubated overnight at 4°C, and blocked with 5% skimmed milk for 2 hours at room temperature. Serum specimens were diluted 1:200, added in duplicates and incubated at room temperature for 1 h. Plates were washed 4 times between the coating and blocking steps. The microtiter plate wells were then incubated (45 min) with peroxidase-conjugated goat antihuman IgG (secondary antibody). Bound secondary antibody was quantified by developing colour with TMB (3, 3', 5, 5'-Tetramethylbenzidine) substrate. Optical density (OD) was read at 450 nm with a reference at 620 nm using a plate reader. Sera of known unexposed individuals were used as controls. All the ELISAs for a given antigen were performed on the same day and on the same ELISA plate for day 0 and day 42 antibody tests of the same individual to eliminate the day to day variations. All samples with optical density readings above 1.4 were diluted further up to 1:1000 to ensure that ODs were less than 1.4. The OD obtained multiplied by the dilution factor. All specimens were analyzed twice or thrice in duplicates and the means of the ELISA OD used in the analysis. If the ELISA OD of an individual's day 42 serum was higher than the same person's corresponding value for the day 0 specimen, the increase was regarded as reflecting a positive antibody anamnestic response or boost. The ratio (D42 ELISA OD)/ (D0 ELISA OD) as well as % increase {(100 x (Day42 ELISA OD-Day0 ELISA OD)/Day0 ELISA OD} was then calculated.
Synthetic peptides
Sero-reactivity to peptides of P. falciparum antigens was determined by ELISA using synthetic peptides which were coated onto ELISA microtiter plate wells. Amino acid sequences of the synthetic peptides [14, 22, 33, 34] representing P. falciparum asexual blood stage proteins were; GLURP: (NH2) CGDKNEKGQHEIVEVEEILPEGC (CONH2), HRP II: (NH2)GCAHHAADA HHAADAHHAADAHHAADGC(CONH2), and MSP3: (NH2) AKEASSYDYILGWEFGGGVPE HKKEEN (CONH2).
Statistical analysis and data presentation
Data were analysed using STATA version 11.0 (Stata Corporation, College Station, Texas, USA) and Graph pad Prism 5. Data were tested for normality using Shapiro-Wilk W test. Differences between medians of IgG levels on day 0 and day 42 were evaluated by Mann-Whitney test while those among three or more groups were assessed by the non-parametric KruskalWallis test. Correlations were identified by Spearman rank test using actual or logarithmically transformed values P values <0.05 were regarded as statistically significant.
Results
In this study, peripheral blood and serum of P. falciparum infected individuals suffering from acute uncomplicated malaria were obtained to determine i) level of CD4 + lymphocytes, ii) IgG sero-reactivity to antigens of lysed parasitized erythrocytes and synthetic polypeptides representing merozoite proteins GLURP, HRP II and MSP3 all of which are important parasite antigens or vaccine candidate molecules [16, 22] . Anti-malarial treatment was then started and 42 days later, the convalescent patients donated another blood specimen which was used to re-estimate the serum IgG against parasite antigens and synthetic peptides. The fold increase in level of anti-P. falciparum antibody was then determined by comparing levels of peptide-specific IgG for day 42 and day 0 as estimated by ELISA. The effect of CD4 + T cell levels and parasite density on magnitude of the sero-reactivity to synthetic peptides was analyzed.
General Characteristics
In this study, 362 participants diagnosed with uncomplicated malaria were enrolled. About 58% (211/362) of the enrolled study participants were female (Table 1) . Forty two percent (109/362)
had not yet attended school for those aged less than five years or had no prior education training, 43% had attained primary level training while 15% had attained secondary level education. Among the study participants enrolled, nearly nineteen percent (68/362) were found to be HIV sero-positive. Of these HIV positive individuals, only seven percent (5/68) reported taking Cotrimoxazole prophylaxis therapy and none was on any anti retroviral therapy (ARV). 136 participants (38%) presented with symptoms of cough on day 0. Approximately 16% (57/362) of the study participants reported having taken an anti-helminthic treatment in the past one month before enrolling into this study. Only three percent (12/362) of the study participants reported that they had taken antimalarial treatment before coming to the health centre. Among the study participants, 67% (241/362) owned a mosquito net in their household and 61% (223/362) of the enrolled subjects slept under a mosquito net in the night preceding the day of enrolment (day 0). Only 38% (138/362) reported owning an insecticide treated bed net (ITN) while 8% (27/362) were not sure on whether their mosquito nets were treated. Enlargement of the spleen was observed in 17% (60/362) of the subjects. The median age of enrolled patients was 9.5 years (IQR: 3-21) and the reported duration of the malaria episode was 3 days (inter quartile range: 2-4). The median axillary temperature measured on day 0 was 37.95°C (IQR: 37.5-38°C).
Relationship between demographic characteristics and boosting after acute uncomplicated P. falciparum malaria
We evaluated the association of all baseline factors and post-infection increase in parasite-specific IgG antibody among the study participants ( Table 2 ). Sex of the study participants and co- infection with HIV were not significantly associated with increase of antibody IgG against GLURP, HRPII and MSP3. Similarly, the duration of fever in days, use of antimalarial therapy before enrolment, self reported use of de-worming drugs, owning a mosquito net within the household and sleeping under a mosquito net in the night preceding the interview were not associated with post-infection increase in specific antibody IgG. However, the presence of a palpable spleen among the study participants was slightly associated with post-infection increase of IgG antibodies to GLURP and MSP3 (p = 0.030 and 0.031, respectively) while anti-HRPII antibodies were hardly affected by presence of palpable spleen.
Sero-prevalence to synthetic peptides on day 0 and age dependence of anti-peptide IgG on days 0 and 42
On day 0, the frequencies of IgG-sero-reactivity against GLURP, MSP3 and HRP II peptides were 75% (271/360), 60% (217/360) and 41% (148/358), respectively. On the other hand, the corresponding levels for IgM sero-prevalence to GLURP, HRP II and MSP3 were 80% (207/ 259), 42% (108/257) and 22% (57/256), respectively. For day 0 blood specimens, anti-peptide IgG levels were significantly associated with age for all the three peptides " Figs 1A Increase in serum anti-parasite IgG after a P. falciparum malaria attack For many subjects, there was a notable increase in the anti-peptide IgG levels from day 0 to day 42 for all the studied peptides GLURP, MSP3 and HRP II. However, the median anti-peptide IgG for HRP II was significantly reduced from day 0 to day 42. "Fig 2" Anamnestic or memory response was expressed as the ratio of ELISA OD units for IgG levels on day 42 and day 0 or as percent increase. The median anamnestic response as depicted by the above ratio or booster effect was 1.21 fold (interquartile range: 0.96-1.55), namely 20% increase. Based on cumulative ELISA data (where ELISA OD units for all three peptides were added up), about 70% (182/ 260) of the study participants produced at least 1.2 fold increase in anti-parasite IgG. " Fig 3B" Thirteen study participants (13/260) produced greater than 2-fold post-diagnosis increase in anti-parasite IgG. "Figs 3A and 3B" Only two percent (5/260) of the subjects showed no increase in peptide-specific IgG antibody following a natural P. falciparum infection. However, for any of the peptides or when the ELISA absorbance units for the three peptides were added together (graph designated 'Summative'), the post-diagnosis fold-increase in anti-parasite IgG did not significantly vary among the three age groups. "Fig 4" Parasite density, CD4 + T-cell counts and antibody anamnestic response
The median asexual parasite density for the HIV negative study participants was 6400 PE/μL (IQR: 3000-24000) while the corresponding value for HIV positive subjects was 5600 PE/μL (IQR: 3000-19531), thus indicating insignificant difference in blood P. falciparum densities between the two groups (p <0.81, Mann-Whitney test). Similarly " Fig 5" , the median CD4 + cell Fig 2. Post-infection increase in parasite-specific IgG. To evaluate memory-response Ab increase elicited by attack of P. falciparum malaria, levels of anti-parasite IgG for day 0 and day 42 were compared. A-C show the antibody IgG levels (ELISA units) against P. falciparum peptides among the study participants on days 0 (circle) and 42 (square). There was a significant increase in the medians of anti-GLURP (p: <0.0001) and anti-MSP3 (P: <0.0001) IgG levels from day 0 to day 42. However, median anti-HRPII IgG significantly reduced after diagnosis and initiation of treatment. When the post-infection fold increase (absorbance ratio: day 42/day 0) was plotted against the CD4+ cell counts " Fig 5" to determine if there was a relationship between post-infection To determine whether post-infection fold-increase of anti-peptide IgG varies by age, the medians of summative ELISA ODs (described in Fig 3) for children less than 5 years (< 5), aged from 5 to 16 years and older than 15 years (> 16) were compared. There was no significant difference among the age groups for all three peptides. Kruskal Wallis test results: GLURP (H = 2.1, 2 df, P = 0.35; MSP3 (H = 2.9, 2 df, P = 0. 
Discussion
Post-infection antibody immune memory response widely occurs in moderate transmission malaria endemic areas
In work reported here, antibody levels to peptides representing three merozoite antigens (GLURP, MSP3 and HRPII) were assessed among residents of a moderately endemic area in Uganda. Two of these synthetic peptides are conserved epitopes of merozoite surface proteins (GLURP and MSP3) recombinant portions of which comprise GMZ2, a leading blood-stage anti-malarial vaccine candidate that was recently tested at clinical trial phases 1 and 2 in Africa [16, 35] . In the present study, serum antibodies against synthetic peptides of GLURP, MSP3 and HRPII were determined by ELISA tests of blood drawn from patients diagnosed with uncomplicated P. falciparum acute infection. The mathematical ratio of ELISA OD units for blood collected on the day of malaria diagnosis and 42 days later were considered to represent a rational estimate of the antibody immune memory (anamnestic) response. It was assumed that patients infected with P. falciparum normally seek treatment at a medical clinic within 2 weeks or so, such that 42 days after diagnosis, the level of blood antibodies on days 0 and 42 would not only provide valid measure of antibody anamnestic response but also enable assessment of post-treatment clinical outcome [29, 30, 36] . The four main findings of this study are 1) the high prevalence of antibodies against conserved epitopes of GLURP, MSP3 and HRPII peptides among PLWHAs and HIV negative participants with uncomplicated malaria in a moderate transmission area of P. falciparum malaria, 2) the significant increase in GLURP and MSP3 specific antibodies from day 0 and day 42 following P. falciparum infection and initiation of anti-malarial drug treatment, 3) finding of comparable antibody anamnestic increases To evaluate the effect of CD4 + cell count and HIV status on post-infection increase of P. falciparum specific antibody, the CD4 + cell counts of PLWHAs (n = 24) and HIV negative participants (n = 91) were first determined. There was no significant difference found in CD4 + cell counts of HIV negative and PLWHAs (p: 0.81, Mann Whitney test). Medians of the respective ratios for summative ELISA OD (as in Fig 4) of day 42 and day 0 sera from PLWHAs and HIV negative participants were likewise not significantly different (Mann Whitney test, p: 0.56).
doi:10.1371/journal.pone.0124297.g005 among different age groups (below 5 years, 5 to 15 years and above 15) 4) unimpaired antibody-producing anamnestic/memory response among early-stage HIV infected people living with HIV/ AIDS (PLWHA). Whereas there were detectable levels of IgG antibodies recognizing all tested peptides representing P. falciparum merozoite proteins GLURP, HRP II and MSP3 on day 0 and day 42 among most study subjects, the IgG levels and sero-prevalence for GLURP peptide were higher than the corresponding serum reactivity to MSP3 or to HRPII. This result corroborates earlier studies which have also reported higher IgG levels and seroprevalence against GLURP in endemic areas [37] . Due to operational limitations, IgG subclass distribution was not investigated in this study although its importance is well recognized [38] and future studies should investigate whether the magnitude and prevalence of post-infection antibody anamnestic responses vary among these immunoglobulin subclasses.
Inter-individual variability
In the present study, it was found that individuals who showed high anti-GLURP antibody levels did not necessarily have high serum IgG against MSP3 or HRP II, suggesting that predisposing host factors may be the cause of the observed variable sero-reactivity to different antigens. But these results also suggest possible differences in immunogenicity of the peptide epitopes as has been previously observed by others [39] . It is likely that immunoassays using extracts of total parasite lysate may find higher sero-prevalence's in all residents of comparable endemic study areas since such whole-cell antigen extracts contain thousands of parasite antigens [40] [41] [42] . Nevertheless, the finding that all study subjects showed IgG sero-reactivity to at least one of the tested three peptides by day 42 (Fig 1) suggests that antibody priming by blood-stage targeted vaccines such as GMZ2 could be boosted by the few infections experienced annually in moderate-transmission endemic regions. However, the number of previous malaria episodes was not determined as this was a cross-sectional study and this could have given us more information regarding the malaria immune status of the study participants.
Five subjects did not show memory to any of the antigens after clearing an acute malaria episode. It is unlikely that all these individuals have never been exposed to malaria before this episode as they reside in an area of moderate malaria transmission. Several different explanations have been offered by others to explain for an apparent failure to produce antibodies to a defined antigen after a malarial infection. Antigenic polymorphism is common in malarial parasites that could explain low frequencies of responses to certain antigens [43] [44] [45] . Similarly, the exposure of an individual to one P. falciparum "strain" may not be adequate to produce a response on exposure to different epitopes of another "strain" [44] . Others include the poor immunogenicity of a malarial antigen which could lead to a lack of or low and undetectable antibody response. Immune responses to some malarial antigens can be genetically controlled, and this could result in permanently weak responses or non-responsiveness of some individuals.
Longevity of antibody immune memory
For most participants of this study, antibody anamnestic increase in level of serum anti-parasite IgG from day 0 to day 42 after malaria diagnosis was observed for at least one or two of the three tested peptides. However human B cell memory, mechanisms and durability of antibody immune memory induced either by P. falciparum natural infections or by vaccine antigens are little understood. There are many reports suggesting that following treatment with antimalarial drugs and resolution of clinical malaria, the levels of antibodies to specific parasite antigens rapidly decline in absence of repeated infections [12, 13] . Indeed, some earlier studies have reported that P. falciparum-specific Ab immune memory is short-lived, surviving for only few weeks to months [44, 46, 47] compared to anti-viral Ab immune memory which lasts up to tens of years [48] . Nevertheless, more recent studies [49] have now shown that P. falciparum can also induce and maintain long-lasting parasite specific memory B cells in humans.
Age dependence of anti-P. falciparum sero-reactivity
In the present study, children aged less than five years had considerably lower levels of specific IgG antibodies against all three peptides studied compared to older children and adults (Fig 1) . These results are consistent with those of many other studies and confirm that anti-P. falciparum antibody immunity increases with age [15, 21, 23] .
Antibody anamnestic response among PLWHAs
While only few (n = 68) people living with human immunodeficiency virus infection/ acquired immuno-deficiency syndrome (HIV/AIDS) (PLWHAs) were enrolled in this study, up to 10% of residents in malaria endemic areas comprise PLWHAs and co infection of P. falciparum and malaria is important [50, 51] . The duration of how long they were infected is not known. However, as shown (Fig 5) , there was no significant difference in the medians of CD4 + cell counts for HIV sero-reactive and sero-negative individuals, suggesting that the enrolled PLWHAs were early-diagnosed HIV cases [52, 53] + cell levels drop to less than 200/uL [59] . Therefore, it would be interesting to investigate antibody anamnestic responses among large numbers of PLWHAs diagnosed with malaria in moderate-transmission malaria areas. Can blood-stage vaccines such as GMZ2 be of value in priming for long-lived boostable anti-malarial immunity among target populations including PLWHAs residing in areas of moderate malaria transmission? The present results (Fig 5) show that HIV sero-negative and early diagnosed PLWHAs with high CD4 + T cell counts (study participants in this study all had higher than 350 CD4 + cells /uL) possess comparable antibody immune memory towards cognate peptide epitopes of GLURP and MSP3, both constituents of the GMZ2 vaccine candidate [17, 37] . If the present study is carried out among children recently immunized with GMZ2 [16] , the results may reveal whether natural infections in moderately low transmission regions can effectively boost the immunity induced by GMZ2 at levels comparable to natural infections [38] . We note that antibody responses to relatively short peptides representing P. falciparum antigens were measured in this study. However, these synthetic short peptides are unlikely to possess conformation of the native protein and may thus not completely bind antibodies elicited by the native protein. For the same reasons these peptides may also bind non specifically to antibodies and may not exactly reflect the antibody response.
In summary, this study set out to determine the antibody immune memory response elicited by an acute P. falciparum malaria episode among residents of a moderate-transmission malaria endemic region. The enrolled subjects included predominantly HIV sero-negative individuals and few early-diagnosed HIV sero-positive cases. The results show that 42 days after diagnosis of acute P. falciparum malaria and initiation of Coartem TM treatment, all the convalescent subjects possess increased serum antibody IgG to at least one of the three tested polypeptides representing important parasite surface proteins GLURP, HRP II and MSP3. A leading bloodstage vaccine candidate, GMZ2 contains GLURP and MSP3 polypeptides. With high blood CD4 + cells counts, all PLWHAs enrolled in the study achieved as high antibody anamnestic responses as HIV sero-negative individuals following acute malaria. Detection of increases in P. falciparum specific IgG antibody in the study subjects after an acute malaria episode suggests that post-infection boosting of specific IgG antibody widely occurs among residents of moderate malaria-transmission endemic areas. This post-infection increase in parasite specific antibody is not influenced by parasite density of the booster infection episode or blood CD4 + cell counts (at least > 350 CD4 /uL) of the convalescent patient. 
